President Joe Biden speaks in the Rose Garden of the White House, in Washington, Nov. 19, 2021. AP Photo/Alex Brandon, File

WASHINGTON — President Joe Biden’s administration is taking steps to expand the availability of the life-saving COVID-19 antiviral treatment Paxlovid, seeking to reassure doctors that there is ample supply for people at high risk of severe illness or death from the virus.

Paxlovid, produced by Pfizer, was first approved in December. Supply of the regimen was initially very limited, but COVID-19 cases across the country have fallen and manufacturing has increased. The White House is now moving to raise awareness of the pill and taking steps to make it easier to access.

The White House said Tuesday it is stepping up outreach to doctors, letting them know they shouldn’t think twice about prescribing the pill to eligible patients. Also, the drug will now be distributed directly to pharmacies, in addition to existing distribution channels run by states. That is expected to boost the number of sites from 20,000 to more than 30,000 next week and eventually to 40,000 locations.

The administration used the pharmacy channel to boost the availability of COVID-19 vaccines more than a year ago.

“Paxlovid will be widely available everywhere in America,” said Dr. Ashish Jha, the White House COVID-19 response coordinator. The drug and antivirals like it “are the key essential tools that we’re going to need to get through the rest of this pandemic,” he said.

Vice President Kamala Harris, who tested positive for COVID-19 on Tuesday, is taking Paxlovid after discussing it with her physicians.

Paxlovid, when administered within five days of symptoms appearing, has been proven to bring about a 90% reduction in hospitalizations and deaths among patients most likely to get severe disease. About 300 Americans are now dying each day from the coronavirus, down from more than 2,600 during the height of the omicron wave earlier this year.

The U.S. has ordered enough supply of the pills for 20 million people, which is estimated to last for several more months. The administration has warned that subsequent deliveries are dependent on Congress approving additional COVID-19 response funding.

“What we need to do is to help American physicians and nurse practitioners and others who can prescribe understand that we now have plenty available and anybody who is eligible, anybody who has high risk, should be getting Paxlovid,” Jha said.

He also encouraged people who test positive to contact their doctors to determine their eligibility for the drug that might prevent severe outcomes.

The Food and Drug Administration authorized Pfizer’s drug for adults and children age 12 or older with a positive COVID-19 test and early symptoms who face the highest risk of severe outcomes. That includes older people and those with conditions like obesity and heart disease, though the drug is not recommended for patients with severe kidney or liver problems.

The administration is also working to expand the number of test-to-treat sites that provide a one-stop-shop for those with COVID-19 to get tested for the virus, consult with a medical professional if they’re positive and fill a prescription for Paxlovid on site. Currently, there are 2,200 locations nationwide, and the administration hopes support from the Department of Health and Human Services, the Federal Emergency Management Agency and pharmacy companies will enable more sites to come online in the coming weeks.